LONDON (Alliance News) - Verona Pharma PLC Thursday said it appointed a new chief financial officer, initially on a part-time basis, to succeed Danny Lowe.
Verona Pharma, which develops drugs to combat respiratory diseases, said Richard Bungay will take on the role of CFO on a part-time basis initially.
"As we see the business grow at the same rate, we will see the involvement and engagement that Richard will spend with us increase," Jan-Anders Karlsson, chief executive, told Alliance News in a telephone interview. "We are a half-virtual company with few employees and our engagement with them, like with Richard, will increase as we grow," he added.
Karlsson declined to comment on whether Bungay would step down from his part-time role as chief executive of Chroma Therapeutics Ltd. if and when his engagement with Verona Pharma increases. Chroma is a biotechnology company working on treatments related to oncology and inflammation.
Verona Pharma shares were Thursday quoted at 2.12 pence, down 0.06 pence, or 2.8%.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2013 Alliance News Limited. All Rights Reserved.
